BMSND Projected Dividend Yield

Bio-Matrix Scientific Group Inc ( OTCBB : BMSND )

Bio-Matrix Scientific Group, through its subsidiary, Regen BioPharma, Inc. (Regen), is engaged in the development of HemaXellerate I, a cellular therapy designed to heal damaged bone marrow. Also development by Regen is a version of HemaXellerate called HemaXellerate II, which is a universal donor endothelial cell based therapeutic and manufactured by obtaining cells from a part of the placenta called the vascular lobules; dCellVax, which is a therapy whereby dendritic cells of the cancer patient are harvested from the body, treated with plasmid DNA and reimplanted in the cancer patient; and NR2F6, which the expression shutting down the immune system's ability to kill cancerous cells.

20 YEAR PERFORMANCE RESULTS